Department of Biliary surgery, Eastern Hepatobiliary Surgery Hospital, The Second Military Medical University, Shanghai, 200438, China.
Department of Surgery, University of Pittsburgh School of Medicine, Pittsburgh, PA, 15213, USA.
Sci Rep. 2018 Feb 19;8(1):3309. doi: 10.1038/s41598-018-21595-4.
Hepatocellular carcinoma with bile duct tumor thrombus (BDTT) is a malignant disease. The most commonly used diagnosis methods for BDTT are MRCP/ERCP, ultrasonic diagnosis or CT scan. However, BDTT is often misdiagnosed as other bile duct diseases, such as extrahepatic cholangiocarcinoma (EHCC), choledochal cyst (Cyst) and common bile duct stone (Stone). Diagnostic methods, which are more accurate and less destructive, are urgently needed. In this paper, we analyzed the small molecule metabolites in the serum of BDTT, Stone, Cyst and EHCC patients and normal people using untargeted GC-MS, and identified 21 metabolites that show different levels among different samples. Using targeted UHPLC-QQQ-MS analysis, we found that several metabolites are significantly changed. ROC curve analysis revealed two metabolites, L-citrulline and D-aspartic acid, as potential biomarkers that can distinguish BDTT from other bile duct diseases.
肝细胞癌伴胆管癌栓（BDTT）是一种恶性疾病。MRCP/ERCP、超声诊断或 CT 扫描是最常用于诊断 BDTT 的方法。然而，BDTT 常被误诊为其他胆管疾病，如肝外胆管癌（EHCC）、胆总管囊肿（Cyst）和胆总管结石（Stone）。因此，急需更准确、破坏性更小的诊断方法。在本研究中，我们采用非靶向 GC-MS 分析了 BDTT、Stone、Cyst 和 EHCC 患者及正常人血清中的小分子代谢物，鉴定出 21 种在不同样本中呈现不同水平的代谢物。采用靶向 UHPLC-QQQ-MS 分析，我们发现几种代谢物发生了显著变化。ROC 曲线分析显示，L-瓜氨酸和 D-天冬氨酸这两种代谢物可作为潜在的生物标志物，有助于区分 BDTT 与其他胆管疾病。
